March 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Bristol Myers Squibb's BMY.N combination treatment for adults and adolescents aged 12 and older with previously untreated Stage III or IV classical Hodgkin's lymphoma.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shailesh Kuber)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.